Scarica l'app Stockscreener
0.9905
12.60%
0.1104
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.8801
Aprire:
$0.935
Volume 24 ore:
1.45M
Relative Volume:
0.97
Capitalizzazione di mercato:
$77.13M
Reddito:
$525.00K
Utile/perdita netta:
$-44.76M
Rapporto P/E:
-1.489
EPS:
-0.6652
Flusso di cassa netto:
$-37.46M
1 W Prestazione:
+9.59%
1M Prestazione:
+19.85%
6M Prestazione:
-41.71%
1 anno Prestazione:
-57.28%
Intervallo 1D:
$0.93
$1.05
Intervallo di 1 settimana:
$0.8671
$1.05
Portata 52W:
$0.7566
$3.31
Cardiff Oncology Inc Stock (CRDF) Company Profile
Nome
Cardiff Oncology Inc
Settore
Industria
Telefono
858-952-7570
Indirizzo
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
0.9915 | 70.69M | 525.00K | -44.76M | -37.46M | -0.6652 |
VRTX
Vertex Pharmaceuticals Inc
|
550.42 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
829.89 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,014.42 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.21 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.13 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Iniziato | Noble Capital Markets | Outperform |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2025-06-24 | Iniziato | Jefferies | Hold |
| 2024-09-06 | Iniziato | Craig Hallum | Buy |
| 2022-01-05 | Iniziato | William Blair | Outperform |
| 2021-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-09 | Ripresa | Maxim Group | Buy |
| 2020-10-22 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-08 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Cardiff Oncology Inc Borsa (CRDF) Ultime notizie
Equities Analysts Offer Predictions for CRDF Q3 Earnings - MarketBeat
Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – DUS:XE7C - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Cardiff Oncology (CRDF) asks investors to double authorized common shares - Stock Titan
Cardiff Oncology (CRDF) Holds Near $0.98 as Consolidation PersistsFibonacci Extension - vinanet.vn
CARDIFF ONCOLOGY, INC. : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - webull.com
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF) - The Globe and Mail
William Blair downgrades Cardiff Oncology (CRDF) to a Hold - The Globe and Mail
CRDF Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
William Blair Downgrades Cardiff Oncology to Market Perform From Outperform - marketscreener.com
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $6 - Moomoo
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty - Investing.com
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty By Investing.com - Investing.com Canada
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Is Cardiff Oncology Inc (CRDF) Moving in the Right Direction Aft - GuruFocus
Cardiff Oncology: Q2 Earnings Snapshot - AOL.com
Cardiff Oncology Q2 operating expenses fall on lower R&D costs - TradingView
Cardiff Oncology (NASDAQ:CRDF) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - The Manila Times
Cardiff Oncology (NASDAQ: CRDF) cuts R&D spend but flags going concern risk - Stock Titan
Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRDF Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage R&D BurnRevenue Guidance Update - vinanet.vn
Cardiff Oncology (CRDF) Holds at $0.85 After Modest Gain; Key Resistance at $0.89 in FocusScalping Stock Signals - vinanet.vn
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Cardiff Oncology (CRDF) Expected to Post Quarterly Earnings on Tuesday - MarketBeat
Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis - TradingKey
BlackRock (CRDF holder) discloses 863,259 Cardiff Oncology shares in 13G/A - Stock Titan
CRDF|Cardiff Oncology Inc|Price:0.952|Chg%:+0.023 - TradingKey
Cardiff Oncology Inc (CRDF) Balance Sheet - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.827|Chg%:-0.011 - TradingKey
Cardiff Oncology Inc (CRDF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cardiff Oncology Inc (CRDF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiff Oncology Inc (CRDF) Institutional Confidence - TradingKey
Cardiff Oncology, Inc. Revenue Breakdown – NASDAQ:CRDF - TradingView
Cardiff Oncology Inc (CRDF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiff Oncology Inc (CRDF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cardiff Oncology Inc (CRDF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cardiff Oncology Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Cardiff Oncology Inc (CRDF) Cash Flow - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.831|Chg%:+0.004 - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.845| - TradingKey
TradingKey - TradingKey
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
CRDF Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Pipeline DevelopmentEarnings Yield Spread - vinanet.vn
Cardiff Oncology completes $10 million financing transaction - TipRanks
Cardiff Oncology CEO Mani Mohindru buys $49,999 of common stock - Investing.com UK
Cardiff Oncology (CRDF) Proxy filing Summary - Quartr
Insider Buying: Mani Mohindru Acquires Shares of Cardiff Oncology Inc (CRDF) - GuruFocus
Cardiff Oncology CEO Mani Mohindru buys $49,999 of common stock By Investing.com - Investing.com Nigeria
Cardiff Oncology Inc Azioni (CRDF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cardiff Oncology Inc Azioni (CRDF) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mohindru Mani | Chief Executive Officer |
Jul 14 '26 |
Buy |
1.46 |
34,364 |
50,000 |
59,067 |
| Mohindru Mani | Chief Executive Officer |
Jun 18 '26 |
Buy |
1.21 |
24,703 |
29,891 |
24,703 |
| PACE GARY W | Director |
Jun 18 '26 |
Buy |
1.22 |
30,000 |
36,600 |
1,356,376 |
1.14%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):